Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 674 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Eczema/Atopic Dermatitis Clear all
Completed Phase 2 Interventional Results available

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

NCT03562377
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo, Tdap vaccine, Meningococcal vaccine
Drug · Biological
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 54 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
39
States / cities
Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Jul 23, 2026, 4:25 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

NCT06238765
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
CorEvitas
Network
Eligibility
10 Years to 15 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2099
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 23, 2026, 4:25 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Skin Microbial Ecology in Atopic Dermatitis

NCT04170244
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis, Healthy
Interventions
AD subject visit sampling procedures, PS subject visit sampling procedures, Healthy control visit sampling procedures
Other
Lead sponsor
University of Rochester
Other
Eligibility
13 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 4:25 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Jul 23, 2026, 4:25 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT07220577
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
GIA632, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Fremont, California • Rockville, Maryland • Hoboken, New Jersey
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 23, 2026, 4:25 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

NCT06224348
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
40
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Jul 23, 2026, 4:25 PM EDT
Completed Phase 4 Interventional Results available

Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit

NCT00654355
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
tacrolimus ointment
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
2 Years to 15 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Jul 23, 2026, 4:25 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
1,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
82
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 4:25 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period

NCT04008784
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2% Topical Application Ointment [EUCRISA], Triamcinolone Acetonide 0.1% Ointment
Drug
Lead sponsor
Clinical Research Center of the Carolinas
Other
Eligibility
2 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Jul 23, 2026, 4:25 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

NCT00605878
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 4:25 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

NCT07205081
View directory record Official record
Conditions
Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
Interventions
ATTO-3712, Placebo
Drug
Lead sponsor
Attovia Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Encinitas, California • Saint Joseph, Missouri
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 23, 2026, 4:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study of CEE321 in Adult Subjects

NCT04612062
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
CEE321
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Jul 23, 2026, 4:25 PM EDT
Completed Phase 3 Interventional Results available

JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

NCT03796676
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, PF-04965842, PF04965842
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
52
States / cities
Birmingham, Alabama • Madera, California • Mission Viejo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Jul 23, 2026, 4:25 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)

NCT05469464
View directory record Official record
Conditions
Atopic Dermatitis, Skin Diseases
Interventions
Orismilast modified release tablets, Placebo
Drug
Lead sponsor
UNION therapeutics
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Canoga Park, California • Fountain Valley, California • Inglewood, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jul 23, 2026, 4:25 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis

NCT00117377
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
20 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
3
States / cities
New York, New York • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2007 · Synced Jul 23, 2026, 4:25 PM EDT
Completed No phase listed Observational

Scratch and Sleep Quantification in Atopic Dermatitis

NCT03490877
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Sleep Disturbance
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
12 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Jul 23, 2026, 4:25 PM EDT
Completed Not applicable Interventional

A Study of a Moisturizing Cream and Baby Wash in the Management of Mild to Moderate Atopic Dermatitis in Infants, Toddlers and Children

NCT04740892
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Wash IP, Cream IP
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
3 Months to 72 Months
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
High Point, North Carolina • Lynchburg, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Jul 23, 2026, 4:25 PM EDT
Completed Phase 3 Interventional

A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy

NCT05958407
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Hand Eczema
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
23
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Jul 23, 2026, 4:25 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating TRIV-509 in Atopic Dermatitis

NCT07167758
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TRIV-509, Placebo
Drug
Lead sponsor
Triveni Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Fountain Valley, California • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Jul 23, 2026, 4:25 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Test the Long-term Safety of BI 655130 in Patients With Atopic Eczema Who Took Part in Study 1368-0032

NCT04086121
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Spesolimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Scottsdale, Arizona • Fort Myers, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jul 23, 2026, 4:25 PM EDT
Completed Not applicable Interventional

Improving Therapeutic Patient Education for Atopic Dermatitis: Evaluation of a Parent Handbook

NCT03722706
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Educational handbook
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Days to 16 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Jul 23, 2026, 4:25 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis

NCT02087943
View directory record Official record
Conditions
Dermatitis, Atopic Dermatitis
Interventions
Apremilast, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
15
States / cities
Phoenix, Arizona • Bakersfield, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Jul 23, 2026, 4:25 PM EDT
Completed Phase 4 Interventional Results available

Twice Daily Altabax Application for the Treatment of Uncomplicated Soft Tissue Infection

NCT01126268
View directory record Official record
Conditions
Impetigo, Folliculitis, Secondarily Infected Eczema, Minor Soft Tissue Infections
Interventions
Retapamulin (Altabax)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
9 Months to 98 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Jul 23, 2026, 4:25 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Skin Conditions

NCT03198390
View directory record Official record
Conditions
Atopic Dermatitis, Hidradenitis Suppurativa, Contact Dermatitis, Psoriasis
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Jul 23, 2026, 4:25 PM EDT